drugset / Trial / NCT00050440
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Phase 2
Completed
50 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
PharmaMar · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.
Timeline
- Start
- 2002-07
- Primary completion
- —
- Completion
- 2004-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trabectedin | Small molecule | 1.3 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 4 mg | Oral |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |